On Wednesday, Hinge Health received an upgrade to its Relative Strength (RS) Rating, from 90 to 93.
How To Use Stock Charts To Stay Profitable And Protected
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the best-performing stocks typically have an RS Rating north of 80 at the beginning of a new climb.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to establish and enter a buying range in heavy trade.
Hinge Health reported 0% EPS growth in the latest quarterly report. Revenue increased 50%.
The company earns the No. 7 rank among its peers in the Medical-Products industry group. Insulet, Boston Scientific and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
